Multiplier AI Blog
Know How Data, AI, & Digital Marketing Can Help Pharma & Life Sciences
Top Agentic AI Use Cases in Pharma (2026)
Most writing about agentic AI in pharmaceuticals describes what agents could do. This guide is organised around a harder question: what has actually shipped, with a date and a name attached, and what remains a slide. The distinction matters more in this category than in most, because the gap between demonstration and deployment is unusually wide — roughly 80% of enterprise applications now embe
Digital Transformation Trends in Pharma and Healthcare: What Actually Changed in 2026
Most digital transformation trend lists are cross-industry and change nothing. This one applies a three-part test — a date, a decision, and a checkable source — to seven developments that reshaped pharma and healthcare in 2026, including a major regulatory deadline that moved while most published guidance still quotes the old one.
Best AI Chatbots & Voice Agents for Hospitals (2026)
In 2026 the Emergency Care Research Institute, an independent patient-safety organisation that publishes an annual list of health technology hazards, named generative AI chatbots the single most dangerous technical risk to patient safety for the year. That is a striking finding to place at the top of a buying guide, and the conclusion most readers will expect from it is wrong. The finding is no
Best AI Tools for Medical Reps & Sales Force Effectiveness (2026)
There is now a large and genuinely useful set of AI tools aimed at medical representatives, and a much larger set of listicles ranking them by feature count. Feature counts are the wrong instrument. A representative's working day is a fixed quantity, most of it spent travelling, waiting and reporting rather than detailing, and the only tools that change commercial outcomes are the ones that eit
Next Best Action Software for Life Sciences: The 2026 Buyer's Guide
Next best action is now the default vocabulary of pharma commercial operations. IQVIA analysis cited across the industry puts deployment at over 80% of major pharma companies running some form of next best action in the field, and McKinsey estimates AI could create $18–30 billion in annual value across pharma commercial functions. Yet walk into most commercial
Patient Intelligence Platforms: Key Features & Evaluation Checklist (2026)
Most hospitals already hold enough data to know which patients are about to stop coming back. The information sits in the HIS, the lab system, the pharmacy, the radiology module, the call centre log and the billing ledger — and almost none of it is connected to a single patient identity. The result is a hospital that can report yesterday's occupancy to two decimal places but cannot answer a sim
Scaling Personalized Physician Content: A Commercial Operations Guide (2026)
Every commercial operations lead in pharma has been handed the same instruction: make the content personal, make it omnichannel, and do it without adding headcount or breaking compliance. The instruction is reasonable. The way most organisations try to execute it is not. They take a content model built for a printed detail aid — one document, one approval, one audience — and ask it to produce t
Best Pharma CDP Platforms for HCP Data (2026)
There are roughly 208 active customer data platform vendors, and only 22% of marketers report high usage of the one they purchased. Those two numbers, taken together, describe a category where buying is much easier than benefiting. Pharmaceutical marketing teams are not exempt — if anything they are more exposed, because the pharma martech conversation routinely conflates five different things
Axtria vs ZS vs Agentic AI Platforms: Choosing a Commercial Partner
Most comparisons of Axtria and ZS treat the choice as a software decision — feature grids, deployment models, pricing structures. That framing was reasonable two years ago. It is now misleading, because within six months in late 2025 and early 2026 both firms answered a more fundamental question in the same way, and the answer changes what a buyer is actually choosing between.
Aktana Alternatives: Next Best Action Platforms Compared (2026)
Search volume for “Aktana alternatives” rose sharply after 7 January 2026, when PharmaForceIQ announced it had acquired Aktana in an asset acquisition with no financial terms disclosed. That timing tells you what most people typing the phrase are actually asking. They are not dissatisfied with the product — Aktana has been a recognised leader in this category for a decade, was named a Leader an
Customer Centricity in Pharma & Life Sciences
In March 2025 Deloitte published a finding that ought to have ended the debate about whether pharmaceutical companies are customer-centric. Eighty-two per cent of life sciences executives said they were satisfied with their organisation's customer engagement strategy. Twenty-eight per cent of healthcare professionals said those strategies met their needs. Both groups were describing the same ac
Territory Alignment in Pharma: A Practical Framework
Territory alignment is usually described as a mapping problem: draw boundaries so that each representative has a fair share of the work and a fair share of the opportunity. That description is accurate and it is why so many alignments fail. Balance is the easiest property to measure and the easiest to optimise, so it becomes the objective — while the property that actually generates revenue, th